A share price of Janux Therapeutics Inc [JANX] is currently trading at $28.71, up 0.70%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The JANX shares have gain 15.30% over the last week, with a monthly amount glided 23.17%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on September 17, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $47. Previously, Truist started tracking the stock with Buy rating on September 10, 2025, and set its price target to $100. On September 10, 2025, Stifel initiated with a Buy rating and assigned a price target of $45 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $72 on September 04, 2025. Piper Sandler initiated its recommendation with an Overweight and recommended $42 as its price target on August 19, 2025. Raymond James started tracking with a Outperform rating for this stock on July 11, 2025, and assigned it a price target of $65. In a note dated December 03, 2024, H.C. Wainwright reiterated a Buy rating on this stock and boosted its target price from $63 to $70.
Janux Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $21.73 and $71.71. Currently, Wall Street analysts expect the stock to reach $57.25 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $28.71 at the most recent close of the market. An investor can expect a potential return of 99.41% based on the average JANX price forecast.
Analyzing the JANX fundamentals
Trailing Twelve Months sales for Janux Therapeutics Inc [NASDAQ:JANX] were 0.44M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 1.26% with Operating Profit Margin at 17.95%, Pretax Profit Margin comes in at 13.09%, and Net Profit Margin reading is 13.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.11 and Total Capital is -0.14. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.00 points at the first support level, and at 27.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.22, and for the 2nd resistance point, it is at 29.73.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Janux Therapeutics Inc [NASDAQ:JANX] is 47.03. Also, the Quick Ratio is 47.03, while the Cash Ratio stands at 2.45. Considering the valuation of this stock, the price to sales ratio is 3921.14, the price to book ratio is 1.72.
Transactions by insiders
Recent insider trading involved Meyer Andrew Hollman, Chief Business Officer, that happened on Oct 28 ’25 when 16665.0 shares were sold. Officer, ANDREW MEYER completed a deal on Oct 28 ’25 to buy 16665.0 shares. Meanwhile, Chief Business Officer Meyer Andrew Hollman sold 3333.0 shares on May 01 ’25.
